Research programme: polo-like kinase 3 protein inhibitors - Clinical Data

Drug Profile

Research programme: polo-like kinase 3 protein inhibitors - Clinical Data

Alternative Names: PLK3 protein inhibitors - Clinical Data

Latest Information Update: 26 Apr 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Avalon Pharmaceuticals
  • Developer Clinical Data
  • Class Small molecules
  • Mechanism of Action Protein-serine-threonine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 26 Apr 2012 Discontinued for Cancer in USA (unspecified route)
  • 13 Apr 2011 Clinical Data has been acquired by Forest Laboratories
  • 29 May 2009 Avalon Pharmaceuticals has been acquired and merged into Clinical Data
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top